
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. has demonstrated a substantial increase in operating margin expansion, now projected to exceed 16%, reflecting strong financial performance and operational efficiency. The company is poised for growth, with anticipated new product launches and accelerated adoption rates in heart and lung transplants, alongside a robust international market presence that bodes well for future revenues. Additionally, an impressive projected 35.2% year-over-year increase in US organ transplant volume and a 40.5% rise in US sales for Q4 positions TransMedics favorably in the competitive landscape for organ preservation technology.
Bears say
TransMedics Group Inc. reported a sequential decline in aviation metrics for Q3, indicating a concerning trend in daily flights and flight hours that could suggest diminishing operational activity and efficiency. The company faced risks related to disappointing adoption of its Organ Care System, intensified competition, and potential regulatory challenges, all of which could adversely affect future growth and market presence. Furthermore, despite revenue growth of 33.1% for product revenues and 30.9% for service revenues, the slight miss against consensus forecasts and lower gross margins of 58.8% raised flags about profitability and overall commercialization effectiveness, contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares